NCT05706324: Phase Ⅰ Clinical Trial of a Candidate COVID-19 Vaccine |
|
|
| Not yet recruiting | 1 | 60 | RoW | Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation, RCVi | Wuhan BravoVax Co., Ltd., National University Hospital, Singapore, Shanghai BravoBio Co., Ltd. | COVID-19 | 12/23 | 07/24 | | |